SCHEMBL293785

SCHEMBL293785

[CH2]CC(CC(=O)O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 8/20 0.56
TDP1 Q9NUW8 2/20 0.46
CPA1 P15085 2/20 0.45
CPB1 P15086 1/20 0.45
CPA3 P15088 1/20 0.45
CPB2 Q96IY4 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.41
NAALAD2 Q9Y3Q0 1/20 0.37
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tricarballylic Acid SCHEMBL1821947 0.82 FOLH1 (0.65) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL34866 0.82 FOLH1 (0.65) FOLH1TDP1CPA1CPB1CPA3
SCHEMBL14591440 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL2462503 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL10710191 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL8329654 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL6757051 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL11728494 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL11736211 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3
Tricarballylic Acid SCHEMBL9087804 0.79 FOLH1 (0.62) FOLH1TDP1CPA1CPB1CPA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed
US-8956807-B2 Method for forming resist pattern, and composition for forming resist underlayer film JSR CORPORATION (JP) 2015-02-17 US disclosed
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
US-8598162-B2 Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-12-03 US disclosed
US-20130101942-A1 METHOD FOR FORMING RESIST PATTERN, AND COMPOSITION FOR FORMING RESIST UNDERLAYER FILM JSR CORPORATION (JP) 2013-04-25 US disclosed
CN-102850336-A DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMA CO LTD 2013-01-02 CN disclosed
EP-2287161-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
EP-2287162-B1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMA CO LTD (JP) 2012-05-09 EP disclosed
EP-1441013-A1 WATERCOLOR INK Mitsui Chemicals, Inc. (JP) 2004-07-28 EP disclosed
EP-0516346-B1 Telomers FMC CORP UK LTD (GB) 1997-04-16 EP disclosed
US-5604291-A ANTISCALING AGENTS FOR AQUEOUS SYSTEMS FMC CORPORATION (UK) LIMITED (GB) 1997-02-18 US disclosed
US-5376731-A Forming phosphonic telomers for addition polymers; antiscaling agents for water systems FMC CORPORATION (UK) LIMITED (GB) 1994-12-27 US disclosed
US-5347008-A Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents CIBA-GEIGY CORPORATION (US) 1994-09-13 US disclosed
EP-0516346-A1 Telomers FMC CORPORATION (UK) LIMITED (GB) 1992-12-02 EP disclosed
US-5152929-A Corrosion inhibitors for water systems CIBA-GEIGY CORPORATION (US) 1992-10-06 US disclosed
EP-0129506-B1 HETEROCYCLICALLY SUBSTITUTED THIO(CYCLO)ALKANE POLYCARBOXYLIC ACIDS CIBA-GEIGY AG (CH) 1991-03-06 EP disclosed
CN-1004134-B Process for preparing water-soluble polymers 第一工业制药株式会社 1989-05-10 CN disclosed
EP-0129506-A2 Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids CIBA-GEIGY AG (CH) 1984-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 FOLH1 3469/4885TDP1 957/4885CPA1 4328/4885
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 FOLH1 1309/4885TDP1 3697/4885CPA1 756/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 FOLH1 1428/4885TDP1 2736/4885CPA1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.